使用BRCAPRO和Myriad模型预测韩国卵巢癌患者的BRCA1和BRCA2突变
该研究在韩国单中心招募2010年11月至2016年8月接受BRCA基因检测的232例卵巢癌患者,比较BRCAPRO与Myriad模型预测的BRCA突变携带概率与实际突变状态。BRCAPRO和Myriad的受试者工作特征曲线下面积分别为0.720和0.747,两模型在有家族史患者中均高估突变概率,在无家族史患者中均低估。作者认为两模型似乎可作为韩国卵巢癌患者BRCA突变风险评估的可接受工具。
要点
- 232例患者中57例(24.6%)BRCA突变阳性,其中BRCA1突变41例、BRCA2突变16例。
- BRCAPRO和Myriad预测BRCA突变的AUC分别为0.720和0.747。
- 两模型在有家族史者中高估突变概率,在无家族史者中低估。
核心结论
- BRCAPRO和Myriad似乎可作为韩国卵巢癌患者BRCA突变风险评估的可接受工具。
研究设计与样本
- 研究为在韩国单中心妇产科招募2010年11月至2016年8月接受BRCA基因检测的个体,共232例,其中99.1%(230/232)为韩国族裔。
- 232例中206例为卵巢癌、26例为乳腺/卵巢双原发癌,36例有一级亲属乳腺癌/卵巢癌家族史。
主要发现
- 57例(24.6%)BRCA突变阳性,其中BRCA1突变41例、BRCA2突变16例。
- 全部患者BRCAPRO和Myriad平均评分分别为6.4%和7.7%。
- BRCA突变阳性患者评分显著高于阴性患者:BRCAPRO 29.0% vs 6.1%(P<0.001),Myriad 12.1% vs 7.7%(P<0.001)。
- BRCAPRO和Myriad预测BRCA突变风险的受试者工作特征曲线下面积分别为0.720和0.747。
- 两模型在有乳腺癌/卵巢癌家族史患者中分别高估突变概率1.55倍和1.50倍,在无家族史患者中均低估为0.54倍。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the predictive efficacies including sensitivity and positive predictive value of the genetic risk prediction model BRCAPRO and the Myriad BRCA risk calculator in Korean ovarian cancer patients. METHODS: Individuals undergoing genetic testing for BRCA mutations from November 2010-August 2016 were recruited from the Department of Obstetrics and Gynecology at a single institute in Korea. The observed BRCA1 and BRCA2 mutation statuses were compared with the predicted carrier probabilities using BRCAPRO and the Myriad BRCA risk calculator. RESULTS: Two hundred thirty-two patients were recruited, of whom 99.1% (230/232) were of Korean ethnicity. Of the 232 individuals, 206 and 26 had ovarian and double primary breast/ovarian cancer, respectively. Thirty-six individuals had a family history of breast/ovarian cancer in first-degree relatives. Fifty-seven patients (24.6%) tested positive for BRCA mutation (41 BRCA1, 16 BRCA2). The mean BRCAPRO and Myriad scores for all patients were 6.4% and 7.7%, respectively. The scores were significantly higher for patients with positive BRCA mutation status (29.0% vs. 6.1%, P<0.001, 12.1% vs. 7.7%, P<0.001, respectively). For all patients, the respective areas under the receiver operating characteristics curves were 0.720 and 0.747 for the BRCAPRO and Myriad models to predict the risk of carrying a BRCA mutation. Both models overestimated the mutation probability in patients with a family history of breast/ovarian cancer (1.55-fold and 1.50-fold, respectively) and underestimated the probability in patients without a family history (both, 0.54-fold). CONCLUSION: BRCAPRO and Myriad seem to be acceptable risk assessment tools for determining the risk of carrying BRCA mutations in Korean ovarian cancer patients.
引用
- Eoh KJ, Park JS, Park HS, et al. BRCA1 and BRCA2 mutation predictions using the BRCAPRO and Myriad models in Korean ovarian cancer patients. Gynecol Oncol. 2017. PMID: 28159408. doi:10.1016/j.ygyno.2017.01.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。